Home > Healthcare > Medical Devices > Diagnostic Devices > Bone Densitometer Market
Bone Densitometer Market size was valued at USD 295.3 million in 2022 and is projected to grow at over 4.9% CAGR from 2023 to 2032. Bone densitometry, also known as dual-energy X-ray absorptiometry (DXA or DEXA), is the most common technique used by bone densitometers. It is a medical device used to measure the density and strength of bones. It is primarily employed in the diagnosis and management of osteoporosis, a condition characterized by low bone density and increased susceptibility to fractures.
Moreover, the rising geriatric population base across the world that is highly susceptible to suffer from several bone disorders will positively influence the bone densitometer market growth. For instance, according to the United Nations (UN) Department of Economic and Social Affairs estimates, the number of individuals aged 65 years or over is anticipated to triple to reach nearly 1.5 billion by the year 2050.
Report Attribute | Details |
---|---|
Base Year: | 2022 |
Bone Densitometer Market Size in 2022: | USD 295.3 Million |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR: | 4.9% |
2032 Value Projection: | USD 476.3 Million |
Historical Data for: | 2018 to 2022 |
No. of Pages: | 195 |
Tables, Charts & Figures: | 414 |
Segments covered: | Technology, Application, End-use, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Further, bone densitometers are essential tools in assessing bone health in older adults and guiding appropriate preventive measures and treatment strategies, thereby owing to the abovementioned factors the adoption rate of bone densitometer devices is on a rise. Additionally, an upsurge in the incidence of osteoporosis and vitamin D deficiency emphasizes the need for bone densitometry as a valuable tool in screening, diagnosis, and management of these conditions. By accurately assessing bone health, bone densitometers assist in risk assessment, treatment planning, and monitoring of these conditions, ultimately improving patient outcomes.
The COVID-19 pandemic impacted the bone densitometer market substantially. The COVID-19 illness and treatment had a negative impact on the survivors' bone health. In April 2022 the National Library of Medicine reported that COVID-19's post-acute sequela can result in secondary osteoporosis. The bone health status of patients that had recovered from the COVID-19 hospitalization was thoroughly assessed at following visits to aid in the early detection and management of osteoporosis issues. Owing to this, the higher the number of people suffering from COVID-19, the greater the need for bone densitometers since early bone density detection and bone inspection become more common.
Consistent technological advancements, including the incorporation of ultrasonic densitometers, digital detectors, and computer-assisted devices indicate ease of use, high comfort, and shortened measurement times. For instance, in January 2022, at the Dubai World Trade Centers edition of MEDLAB Middle East, Beckman Coulter showcased their newly released DxA 5000 Fit workflow-automation system.
Therefore, it is anticipated that the target market will expand as a result of all these technological developments, product launches, and collaboration initiatives. Furthermore, traditional film-based X-ray detectors have been largely replaced by digital medical X-ray detectors. These detectors capture X-ray images in a digital format, allowing for immediate image acquisition, enhanced image quality, and efficient data processing.
Based on technology, the bone densitometer market is segmented into axial bone densitometry and peripheral bone densitometry. The axial bone densitometry segment witnessed the largest revenue size of USD 160.2 million in 2022 and is estimated to cross USD 264.6 million by 2032. The most used method for determining bone density in the body is dual-energy X-ray absorptiometry (DEXA). Due to its great precision, ease of use, and safety for both adults and children, this equipment is frequently used for both central and peripheral bone mineral density (BMD) scans.
Osteopenia and osteoporosis are diagnosed with the help of dual-energy x-ray absorptiometry (DEXA or DXA). Additionally, high prevalence of osteoporosis among the population base, the rising adoption rate can be linked to dual-energy x-ray absorptiometry's ability to satisfy a variety of clinical needs.
Based on application bone densitometer market is bifurcated osteoporosis and osteopenia diagnosis, cystic fibrosis diagnosis, chronic kidney diseases diagnosis, rheumatoid arthritis diagnosis, body composition measurement. The osteoporosis and osteopenia segment is anticipated to reach USD 155.6 million by 2032. Osteoporosis and osteopenia are common conditions, especially among older adults. The increasing prevalence of these conditions drives the need for bone densitometry to accurately diagnose and monitor bone health. Additionally, bone densitometers play a crucial role in assessing fracture risk associated with osteoporosis and osteopenia. By measuring bone mineral density (BMD) at specific sites, such as the hip and spine, bone densitometry helps determine an individual's likelihood of experiencing fractures.
The bone densitometer market is segmented by end-use into hospitals, specialty centers, and others. Hospitals segment accounted for 49% of market share in 2022, due to the growing tendency of government health organizations to promote advanced diagnostic tools that provide rapid results is one of the primary factors. Hospitals are also utilising fully automated technologies that can identify this condition early in the existing setting.
Additionally, hospitals play a crucial role in the diagnosis and management of osteoporosis. Bone densitometry, particularly dual-energy X-ray absorptiometry (DXA), is the primary diagnostic tool for osteoporosis. Hospitals need bone densitometers to accurately assess bone mineral density (BMD) and evaluate fracture risk in patients. This information is vital for making treatment decisions and implementing preventive measures.
U.S. bone densitometer market size held more than USD 103.6 million in 2022, owing to different collaborative initiatives performed by various companies to increase their R&D capabilities and maintain high medical standards. The increasing use of modern technology in healthcare systems, as well as the expanding burden of chronic diseases, are driving the U.S. market growth.
For instance, the American Cancer Society estimates that there will be 3,910 new instances of bone and joint cancer in the U.S. in 2022, of which 1,750 will be in females and 2,160 will be in males. Since cancer cells and cancer-specific medications have negative effects on bone cells, cancer is a major cause of bone loss and fractures. Additionally, rising number of people affected with bone related disorders is boosting the demand for orthopaedic devices such as the bone densitometer system that aids in determining the risk of fractures, the rising incidence of cancer also contributes to the expansion of the market in the region.
Some of the notable key companies operating in the bone densitometer market include:
These companies are implementing various growth strategies such as collaborations, partnerships, acquisitions & mergers, and new product development and launches to strengthen type offerings as well as gain a competitive edge over others.
Click here to Buy Section of this Report
Market, By Type
Market, By Application
Market, By End-use
The above information has been provided for the following regions and countries: